A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT ID: NCT06312137
Last Updated: 2026-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
780 participants
INTERVENTIONAL
2024-04-03
2034-10-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04619797
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pembrolizumab + Sacituzumab tirumotecan
Participants will receive pembrolizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W) for up to 12 weeks + double-platinum chemotherapy per neoplasm histology classification at the investigator's discretion as neoadjuvant therapy prior to surgery; followed by sacituzumab tirumotecan 4 mg/kg IV infusion every 2 weeks (Q2W) for up to 12 doses (\~24 weeks) with pembrolizumab monotherapy 200 mg IV infusion every 6 weeks (Q6W) for up to 7 cycles (\~42 weeks).
Sacituzumab tirumotecan
Sacituzumab tirumotecan to be administered as 4mg/kg IV infusion q2w for up to 24 weeks
Pembrolizumab
Pembrolizumab to be administered 400mg by IV infusion q6w for up to 42 weeks
Rescue medication
Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.
Pembrolizumab
Participants will receive pembrolizumab 200 mg intravenous (IV) infusion Q3W for up to 12 weeks + double-platinum chemotherapy per neoplasm histology classification at the investigator's discretion as neoadjuvant therapy prior to surgery; followed by pembrolizumab monotherapy 200 mg IV infusion Q6W for up to 7 cycles (\~42 weeks).
Pembrolizumab
Pembrolizumab to be administered 400mg by IV infusion q6w for up to 42 weeks
Cisplatin
Cisplatin is administered as 75 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in neoadjuvant phase
Pemetrexed
Pemetrexed will be administered in the neoadjuvant phase as 500 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in participants with nonsquamous NSCLC.
Gemcitabine
Gemcitabine will be administered in the neoadjuvant phase as 1000 mg/m2 or 1250 mg/m2 IV infusion on day 1 and day 8 q3w for up to 24 weeks as background treatment in participants with squamous NSCLC.
Carboplatin
Carboplatin will be administered in the neoadjuvant phase as AUC 5 mg/mL/min or AUC 6 mg/mL/min IV infusion q3w for up to 12 weeks as background treatment.
Paclitaxel
Paclitaxel will be administered in the neoadjuvant phase as 175 mg/m2 or 200 mg/m2 IV infusion q3w for up to 12 weeks as background treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sacituzumab tirumotecan
Sacituzumab tirumotecan to be administered as 4mg/kg IV infusion q2w for up to 24 weeks
Pembrolizumab
Pembrolizumab to be administered 400mg by IV infusion q6w for up to 42 weeks
Cisplatin
Cisplatin is administered as 75 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in neoadjuvant phase
Pemetrexed
Pemetrexed will be administered in the neoadjuvant phase as 500 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in participants with nonsquamous NSCLC.
Gemcitabine
Gemcitabine will be administered in the neoadjuvant phase as 1000 mg/m2 or 1250 mg/m2 IV infusion on day 1 and day 8 q3w for up to 24 weeks as background treatment in participants with squamous NSCLC.
Carboplatin
Carboplatin will be administered in the neoadjuvant phase as AUC 5 mg/mL/min or AUC 6 mg/mL/min IV infusion q3w for up to 12 weeks as background treatment.
Paclitaxel
Paclitaxel will be administered in the neoadjuvant phase as 175 mg/m2 or 200 mg/m2 IV infusion q3w for up to 12 weeks as background treatment.
Rescue medication
Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has confirmation that either epidermal growth factor receptor (EGFR)-directed or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated as primary therapy
* Is able to undergo surgery based on opinion of investigator after consultation with surgeon
* Is able to receive neoadjuvant pembrolizumab and platinum-based doublet chemotherapy
* Applies to screening for the adjuvant period only, before randomization: Has not achieved pathological complete response (pCR) at surgery by local review of pathology.
* Applies to screening for the adjuvant period only, before randomization: Tumor tissue sample from surgical resection has been provided for determination of programmed cell death ligand 1 (PD-L1) and trophoblast cell surface antigen 2 (TROP2) status by central vendor before randomization into the adjuvant period
* Applies to screening for the adjuvant period only, before randomization: Confirmed to be disease-free based on re-baseline radiological assessment as documented by contrast enhanced chest/abdomen/pelvis computed tomography (CT) (or magnetic resonance imaging (MRI)) within 28 days before randomization
* Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible
* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load at screening
* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at least 4 weeks before the start of study intervention
Exclusion Criteria
* NSCLC involving the superior sulcus
* Large cell neuro-endocrine cancer (LCNEC)
* Sarcomatoid tumor
* Diagnosis of SCLC or, for mixed tumors, presence of small cell elements
* Has Grade ≥2 peripheral neuropathy
* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QT corrected for heart rate by Fridericia's cube root formula (QTcF) interval to \>480 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention
* Has received prior neoadjuvant therapy for their current NSCLC diagnosis
* Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention
* Has received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids
* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
* Has a known additional malignancy that is progressing or has required active treatment within the past 5 years
* Has an active autoimmune disease that has required systemic treatment in the past 2 years
* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
* Has an active infection requiring systemic therapy
* Is an HIV-infected participant with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
* Has a concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV deoxyribonucleic acid (DNA)) and Hepatitis C virus (defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA)) infection
* Has a history of allogeneic tissue/solid organ transplant
* Has not adequately recovered from major surgery or have ongoing surgical complications
* Severe hypersensitivity (≥Grade 3) to study intervention, any of its excipients, and/or to another biologic therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060)
Little Rock, Arkansas, United States
Highlands Oncology Group-Research Department ( Site 0062)
Springdale, Arkansas, United States
Beverly Hills Cancer Center ( Site 0070)
Beverly Hills, California, United States
The Angeles Clinic and Research Institute ( Site 0040)
Los Angeles, California, United States
The Angeles Clinic and Research Institute- A Cedars-Sinai Affiliate ( Site 0079)
Los Angeles, California, United States
UCLA Clinical & Translational Research Center (CTRC) ( Site 0033)
Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian ( Site 0096)
Newport Beach, California, United States
San Francisco Oncology Associates ( Site 0066)
San Francisco, California, United States
Stamford Hospital ( Site 0083)
Stamford, Connecticut, United States
Mayo Clinic in Florida ( Site 0014)
Jacksonville, Florida, United States
Mount Sinai Cancer Center ( Site 0038)
Miami Beach, Florida, United States
Mid Florida Hematology and Oncology Center ( Site 0018)
Orange City, Florida, United States
Emory University School of Medicine-Phase I ( Site 0056)
Atlanta, Georgia, United States
Northside Hospital ( Site 0055)
Atlanta, Georgia, United States
Centricity Research Columbus Cancer Center ( Site 0005)
Columbus, Georgia, United States
Southeastern Regional Medical Center ( Site 0065)
Newnan, Georgia, United States
Lewis Cancer and Research Pavilion ( Site 0063)
Savannah, Georgia, United States
Archbold Cancer Center ( Site 0071)
Thomasville, Georgia, United States
Edward-Elmhurst Healthcare, Elmhurst Hospital-Nancy W. Knowles Cancer Center ( Site 0017)
Elmhurst, Illinois, United States
Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0078)
Naperville, Illinois, United States
Parkview Research Center at Parkview Regional Medical Center ( Site 0089)
Fort Wayne, Indiana, United States
Indiana University Health Arnett Cancer Center ( Site 0076)
Lafayette, Indiana, United States
Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0061)
Edgewood, Kentucky, United States
LSU Health Baton Rouge North Clinic ( Site 4003)
Baton Rouge, Louisiana, United States
Our Lady of the Lake Physician Group-Medical Oncology ( Site 0080)
Baton Rouge, Louisiana, United States
New England Cancer Specialists ( Site 0095)
Westbrook, Maine, United States
Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0027)
Minneapolis, Minnesota, United States
Mayo Clinic - Rochester ( Site 0073)
Rochester, Minnesota, United States
Mercy South - David M Sindelar Cancer Center ( Site 0098)
St Louis, Missouri, United States
Mercy Research - David C. Pratt Cancer Center ( Site 0006)
St Louis, Missouri, United States
Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0037)
Reno, Nevada, United States
Atlantic Health Morristown Medical Center ( Site 0077)
Morristown, New Jersey, United States
Cayuga Medical Center ( Site 0086)
Ithaca, New York, United States
Stony Brook University-Cancer Center ( Site 0054)
Stony Brook, New York, United States
White Plains Hospital ( Site 0091)
White Plains, New York, United States
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0057)
Fargo, North Dakota, United States
Hightower Clinical, LLC ( Site 0084)
Oklahoma City, Oklahoma, United States
Oregon Health and Science University ( Site 0052)
Portland, Oregon, United States
Penn State Milton S. Hershey Medical Center-Penn State Cancer Institute ( Site 0059)
Hershey, Pennsylvania, United States
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068)
Lancaster, Pennsylvania, United States
Saint Joseph's Candler Health System ( Site 4010)
Bluffton, South Carolina, United States
Medical University of South Carolina-Hollings Cancer Center ( Site 0045)
Charleston, South Carolina, United States
Sanford Cancer Center ( Site 0053)
Sioux Falls, South Dakota, United States
Avera Cancer Institute- Research ( Site 0090)
Sioux Falls, South Dakota, United States
University of Tennessee Medical Center Knoxville ( Site 0082)
Knoxville, Tennessee, United States
Millennium Research & Clinical Development ( Site 0039)
Houston, Texas, United States
Huntsman Cancer Institute ( Site 0042)
Salt Lake City, Utah, United States
Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0213)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Hospital Británico de Buenos Aires-Oncology ( Site 0207)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Sanatorio Británico-Clinical Oncology Department ( Site 0206)
Rosario, Santa Fe Province, Argentina
Sanatorio Parque ( Site 0205)
Rosario, Santa Fe Province, Argentina
Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L ( Site 0217)
San Miguel de Tucumán, Tucumán Province, Argentina
Hospital Aleman-Oncology ( Site 0202)
Buenos Aires, , Argentina
Hospital Privado Universitario de Córdoba-Hematology and Oncology ( Site 0204)
Córdoba, , Argentina
Westmead Hospital ( Site 0701)
Westmead, New South Wales, Australia
The Prince Charles Hospital ( Site 0700)
Brisbane, Queensland, Australia
Fiona Stanley Hospital-Medical Oncology ( Site 0705)
Murdoch, Western Australia, Australia
Medizinische Universitaet Innsbruck-Department for Internal Medicine V ( Site 1403)
Innsbruck, Tyrol, Austria
Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 1402)
Linz, Upper Austria, Austria
Standort Penzing der Klinik Ottakring-Abteilung für Atemwegs-und Lungenkrankheiten ( Site 1401)
Vienna, , Austria
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 1400)
Vienna, , Austria
Antwerp University Hospital-Thoracic Oncology ( Site 1503)
Edegem, Antwerpen, Belgium
Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godi ( Site 1502)
Yvoir, Namur, Belgium
VITAZ ( Site 1500)
Sint-Niklaas, Oost-Vlaanderen, Belgium
Liga Norte Riograndense Contra o Câncer ( Site 0301)
Natal, Rio Grande do Norte, Brazil
Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0303)
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceição ( Site 0302)
Porto Alegre, Rio Grande do Sul, Brazil
Instituto de Oncologia Saint Gallen ( Site 0319)
Santa Cruz do Sul, Rio Grande do Sul, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0304)
Barretos, São Paulo, Brazil
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0313)
São José do Rio Preto, São Paulo, Brazil
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0100)
Greenfield Park, Quebec, Canada
Centre Hospitalier de l'Université de Montréal ( Site 0104)
Montreal, Quebec, Canada
St. Marys Hospital Center ( Site 0107)
Montreal, Quebec, Canada
McGill University Health Centre ( Site 0105)
Montreal, Quebec, Canada
FALP-UIDO ( Site 0401)
Providencia, Region M. de Santiago, Chile
Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0404)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 0400)
Santiago, Region M. de Santiago, Chile
ONCOCENTRO APYS-ACEREY ( Site 0410)
Viña del Mar, Región de Valparaíso, Chile
Beijing Cancer hospital-Thoracic Surgery department I ( Site 1301)
Beijing, Beijing Municipality, China
Beijing Peking Union Medical College Hospital-Thoracic surgery department ( Site 1302)
Beijing, Beijing Municipality, China
Peking University People's Hospital. ( Site 1300)
Beijing, Beijing Municipality, China
Fujian Cancer Hospital-oncology department ( Site 1314)
Fuzhou, Fujian, China
The First Affiliated Hospital of Guangzhou Medical University-thoracic surgery department ( Site 1320)
Guangzhou, Guangdong, China
Southern Medical University Nanfang Hospital-Thoracic surgery department ( Site 1313)
Guangzhou, Guangdong, China
Henan Cancer Hospital-henan cancer hospital ( Site 1316)
Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology-Thoracic Surgery ( Site 1306)
Wuhan, Hubei, China
Hubei Cancer Hospital ( Site 1308)
Wuhan, Hubei, China
Xiangya Hospital Central South University-Thoracic surgery ( Site 1311)
Changsha, Hunan, China
Hunan Cancer Hospital ( Site 1312)
Changsha, Hunan, China
Nanjing First Hospital ( Site 1310)
Nanjing, Jiangsu, China
The First Affiliated Hospital of Soochow University-Thoracic Surgery Department ( Site 1318)
Suzhou, Jiangsu, China
The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 1330)
Nanchang, Jiangxi, China
The First Hospital of Jilin University ( Site 1324)
Changchun, Jilin, China
The Second Affiliated Hospital of Air Force Medical University ( Site 1332)
Xi'an, Shaanxi, China
Shandong Cancer Hospital ( Site 1321)
Jinan, Shandong, China
Zhongshan Hospital Fudan University ( Site 1325)
Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital-Thoracic Surgery department ( Site 1304)
Shanghai, Shanghai Municipality, China
Sichuan Cancer hospital. ( Site 1327)
Chengdu, Sichuan, China
The Second People's Hospital of Neijiang ( Site 1322)
Neijiang, Sichuan, China
Yunnan Province Cancer Hospital ( Site 1315)
Kunming, Yunnan, China
The first Affiliated Hospital, Zhejiang University School of-Thoracic Cardiovascular Surgery Ward ( Site 1303)
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital ( Site 1309)
Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 1328)
Hangzhou, Zhejiang, China
Taizhou Hospital of Zhejiang Province ( Site 1329)
Linhai, Zhejiang, China
Ningbo No. 2 Hospital ( Site 1305)
Ningbo, Zhejiang, China
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 1600)
Brno, Brno-mesto, Czechia
Nemocnice AGEL Ostrava - Vitkovice a.s.-Plicni oddeleni ( Site 1601)
Ostrava, Ostrava Mesto, Czechia
CHRU de Brest ( Site 1804)
Brest, Finistere, France
CHU de Toulouse - Hopital Larrey-service de pneumologie ( Site 1801)
Toulouse, Haute-Garonne, France
CHU Charles Nicolle ( Site 1803)
Rouen, Haute-Normandie, France
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren ( Site 1805)
Limoges, Haute-Vienne, France
Clinique Teissier Groupe ( Site 1811)
Valenciennes, Nord, France
Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 1810)
Clermont-Ferrand, Puy-de-Dome, France
Hospices Civils de Lyon - Hopital Louis Pradel ( Site 1809)
Bron, Rhone, France
HIA Sainte Anne ( Site 1800)
Toulon, Var, France
Hôpital Tenon ( Site 1802)
Paris, , France
Groupe hospitalier Paris saint Joseph. ( Site 1807)
Paris, Île-de-France Region, France
Klinikum Esslingen-Klinik für Kardiologie und Pneumologie ( Site 1914)
Esslingen am Neckar, Baden-Wurttemberg, Germany
Universitaetsklinikum Regensburg ( Site 1907)
Regensburg, Bavaria, Germany
Lungenklinik Hemer ( Site 1905)
Hemer, North Rhine-Westphalia, Germany
Katholisches Klinikum Koblenz ( Site 1911)
Koblenz, Rhineland-Palatinate, Germany
Universitätsklinikum Leipzig ( Site 1915)
Leipzig, Saxony, Germany
Krankenhaus Martha-Maria Halle-Dölau-Klinik für Innere Medizin II ( Site 1908)
Halle, Saxony-Anhalt, Germany
Zentralklinik Bad Berka-Klinik für Hämatologie und Onkologie ( Site 1902)
Bad Berka, Thuringia, Germany
SRH Wald-Klinikum Gera-Lungenkrebszentrum ( Site 1900)
Gera, Thuringia, Germany
Evangelische Lungenklinik Berlin-Pneumologie ( Site 1904)
Berlin, , Germany
Charité Campus Virchow-Klinikum-Department of Infectious Diseases and Pulmonary Medicine ( Site 1903)
Berlin, , Germany
Vivantes Hospital Spandau-Klinik für Innere Medizin, Hämatologie, Onkologie und Gastroenterologie- ( Site 1912)
Berlin, , Germany
Helios Klinikum Emil von Behring Berlin-Zehlendorf ( Site 1916)
Berlin, , Germany
UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 2006)
Pátrai, Achaia, Greece
251 Hellenic Air Force General Hospital ( Site 2003)
Athens, Attica, Greece
THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 2000)
Athens, Attica, Greece
Athens Medical Center ( Site 2005)
Athens, Attica, Greece
Metaxa Cancer Hospital of Piraeus ( Site 2002)
Piraeus, Attica, Greece
University General Hospital of Heraklion-Internal Medicine-Oncology ( Site 2001)
Heraklion, Irakleio, Greece
University General Hospital of Larissa-Oncology Clinic ( Site 2004)
Larissa, Thessaly, Greece
European Interbalkan Medical Center ( Site 2007)
Thessaloniki, , Greece
Queen Mary Hospital ( Site 3400)
Hksar, , Hong Kong
Hong Kong United Oncology Centre ( Site 3403)
Kowloon, , Hong Kong
Queen Elizabeth Hospital ( Site 3402)
Yau Ma Tei, , Hong Kong
Rambam Health Care Campus-Oncology Division ( Site 2203)
Haifa, , Israel
Shaare Zedek Medical Center ( Site 2206)
Jerusalem, , Israel
Rabin Medical Center ( Site 2204)
Petah Tikva, , Israel
Sheba Medical Center ( Site 2200)
Ramat Gan, , Israel
Humanitas Istituto Clinico Catanese ( Site 2315)
Misterbianco, Catania, Italy
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 2302)
Meldola, Emilia-Romagna, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 2300)
Milan, Lombardy, Italy
San Paolo - ASST SANTI PAOLO E CARLO ( Site 2314)
Milan, Lombardy, Italy
Fondazione IRCCS San Gerardo dei Tintori-Oncologia ( Site 2301)
Monza, Lombardy, Italy
Istituto Nazionale Tumori Regina Elena-Oncologia Medica 2 ( Site 2309)
Rome, Roma, Italy
Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 2307)
Florence, Tuscany, Italy
Humanitas Gavazzeni-ONCOLOGY ( Site 2310)
Bergamo, , Italy
Ospedale San Martino ( Site 2313)
Genova, , Italy
Ospedale San Raffaele-Oncologia Medica ( Site 2311)
Milan, , Italy
Azienda Ospedaliero Universitaria di Parma-UO Oncologia Medica ( Site 2312)
Parma, , Italy
Fondazione IRCCS Policlinico San Matteo-Oncology ( Site 2303)
Pavia, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 2306)
Roma, , Italy
APSS- Presidio Ospedaliero S. Chiara ( Site 2304)
Trento, , Italy
National Cancer Center Hospital East ( Site 1202)
Kashiwa, Chiba, Japan
National Hospital Organization Shikoku Cancer Center ( Site 1216)
Matsuyama, Ehime, Japan
Hospital of the University of Occupational and Environmental Health, Japan ( Site 1217)
Kitakyushu, Fukuoka, Japan
Kobe City Medical Center General Hospital ( Site 1213)
Kobe, Hyōgo, Japan
St. Marianna University Hospital ( Site 1207)
Kawasaki, Kanagawa, Japan
Kanagawa Cancer Center ( Site 1206)
Yokohama, Kanagawa, Japan
Kansai Medical University Hospital ( Site 1211)
Hirakata, Osaka, Japan
Kindai University Hospital ( Site 1212)
Sakai, Osaka, Japan
Saitama Prefectural Cancer Center ( Site 1201)
Kitaadachi-gun, Saitama, Japan
Juntendo University Hospital ( Site 1204)
Bunkyo-ku, Tokyo, Japan
Tokyo Medical University Hospital ( Site 1203)
Shinjuku, Tokyo, Japan
National Hospital Organization Kyushu Cancer Center ( Site 1218)
Fukuoka, , Japan
Fukushima Medical University Hospital ( Site 1200)
Fukushima, , Japan
Hiroshima University Hospital ( Site 1215)
Hiroshima, , Japan
Niigata Cancer Center Hospital ( Site 1208)
Niigata, , Japan
Okayama University Hospital ( Site 1214)
Okayama, , Japan
Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 1210)
Osaka, , Japan
Nippon Medical School Hospital ( Site 1205)
Tokyo, , Japan
Yamagata University Hospital ( Site 1219)
Yamagata, , Japan
CIO - Centro de Inmuno-Oncología de Occidente ( Site 0506)
Guadalajara, Jalisco, Mexico
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Servicio de Oncología ( Site 0508)
Monterrey, Nuevo León, Mexico
Centro de Investigacion Clinica de Oaxaca ( Site 0509)
Oaxaca City, Oaxaca, Mexico
Unidad de Mastologia Avanzada de Chihuahua S.A de C.V ( Site 0504)
Chihuahua City, , Mexico
Mediadvance Clinical ( Site 0502)
Chihuahua City, , Mexico
Oaxaca Site Management Organization S.C. ( Site 0507)
Oaxaca City, , Mexico
Amphia Ziekenhuis, locatie Breda Molengracht-long oncologie ( Site 3453)
Breda, North Brabant, Netherlands
Isala, locatie Zwolle-Poli Longziekten ( Site 3454)
Zwolle, Overijssel, Netherlands
Leids Universitair Medisch Centrum-Longziekten ( Site 3451)
Leiden, South Holland, Netherlands
Erasmus Medisch Centrum ( Site 3452)
Rotterdam, South Holland, Netherlands
Meander Medisch Centrum-Researchbureau Longgeneeskunde ( Site 3458)
Amersfoort, Utrecht, Netherlands
University Medical Center Groningen ( Site 3459)
Groningen, , Netherlands
Martini Ziekenhuis ( Site 3460)
Groningen, , Netherlands
Sint Antonius Ziekenhuis ( Site 3455)
Utrecht, , Netherlands
Auckland City Hospital ( Site 0800)
Auckland, , New Zealand
Akershus Universitetssykehus ( Site 2501)
Lørenskog, Akershus, Norway
Drammen Sykehus, Vestre Viken HF ( Site 2502)
Drammen, Buskerud, Norway
Sykehuset Innlandet HF Gjøvik ( Site 2503)
Gjøvik, Oppland, Norway
Oslo universitetssykehus HF. Radiumhospitalet ( Site 2504)
Oslo, , Norway
IPOR Instituto Peruano de Oncología & Radioterapia-Centro de Investigación ( Site 0604)
Lima, , Peru
Oncosalud ( Site 0602)
Lima, , Peru
INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-Medical Oncology ( Site 0600)
Lima, , Peru
Instituto Neuro Cardiovascular de las Americas ( Site 0607)
Lima, , Peru
Hospital Nacional Edgardo Rebagliati Martins-medical oncology ( Site 0603)
Lima, , Peru
Wielkopolskie Centrum Pulmonologii i Torakochirurgii-Oddzial Onkologii Klinicznej z Pododdzialem Dz ( Site 2602)
Poznan, Greater Poland Voivodeship, Poland
Uniwersytecki Szpital Kliniczny nr 4 w Lublinie ( Site 2611)
Lublin, Lublin Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 2600)
Warsaw, Masovian Voivodeship, Poland
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 2601)
Przemyśl, Podkarpackie Voivodeship, Poland
Bialostockie Centrum Onkologii ( Site 2604)
Bialystok, Podlaskie Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne ( Site 2610)
Gdansk, Pomeranian Voivodeship, Poland
Szpital Specjalistyczny w Prabutach Spolka z o.o. ( Site 2613)
Prabuty, Pomeranian Voivodeship, Poland
Warmińsko - Mazurskie Centrum Chorób Płuc w Olsztynie-Oddzial Onkologii z Pododdzialem Chemioterapii ( Site 2606)
Olsztyn, Warmian-Masurian Voivodeship, Poland
UNIDADE LOCAL DE SAUDE DE MATOSINHOS-Serviço de Oncologia ( Site 2705)
Matosinhos Municipality, Porto District, Portugal
Instituto Portugês de Oncologia de Coimbra Francisco Gentil-Oncologia Médica ( Site 2704)
Coimbra, , Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 2702)
Porto, , Portugal
MEMORIAL HEALTHCARE INTERNATIONAL S.R.L.. ( Site 2803)
Bucharest, București, Romania
Cardiomed SRL Cluj-Napoca-Medical Oncology ( Site 2801)
Cluj-Napoca, Cluj, Romania
SC Radiotherapy Center Cluj SRL-Oncologie Medicala ( Site 2802)
Florești, Cluj, Romania
Centrul de Oncologie Sfantul Nectarie-Medical ( Site 2805)
Craiova, Dolj, Romania
Spitalul Clinic Municipal De Urgenta Timisoara ( Site 2806)
Timișoara, Timiș County, Romania
SC ONCO CARD SRL ( Site 2808)
Brasov, , Romania
Spitalul Clinic De Urgenta Prof Dr Agrippa Ionescu ( Site 2804)
Bucharest, , Romania
Institutul Regional de Oncologie ( Site 2807)
Iași, , Romania
National Cancer Center-Lung Cancer Center ( Site 1002)
Goyang-si, Kyonggi-do, South Korea
Seoul National University Bundang Hospital-Medical Oncology ( Site 1003)
Seongnam, Kyonggi-do, South Korea
The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 1001)
Suwon, Kyonggi-do, South Korea
Chungbuk National University Hospital-Internal medicine ( Site 1000)
Cheongju-si, North Chungcheong, South Korea
Keimyung University Dongsan Hospital CRC room 1 ( Site 1006)
Daegu, Taegu-Kwangyokshi, South Korea
Asan Medical Center-Lung Cancer Center ( Site 1005)
Seoul, , South Korea
Samsung Medical Center-Division of Hematology/Oncology ( Site 1004)
Seoul, , South Korea
Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 2901)
L'Hospitalet de Llobregat, Barcelona, Spain
CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 2905)
Santiago de Compostela, La Coruna, Spain
Hospital Insular de Gran Canaria-Oncology ( Site 2903)
Las Palmas de Gran Canaria, Las Palmas, Spain
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 2902)
Pozuelo de Alarcón, Madrid, Spain
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 2900)
Barcelona, , Spain
Hospital Clinico San Carlos-Oncology Department ( Site 2904)
Madrid, , Spain
CHUV (centre hospitalier universitaire vaudois) ( Site 3003)
Lausanne, Canton of Vaud, Switzerland
Kantonsspital Graubünden-Medizin ( Site 3006)
Chur, Kanton Graubünden, Switzerland
Kantonsspital Münsterlingen - Spital Thurgau AG ( Site 3005)
Münsterlingen, Thurgau, Switzerland
HFR Fribourg - Hôpital Cantonal ( Site 3004)
Fribourg, , Switzerland
National Taiwan University Cancer Center (NTUCC) ( Site 1105)
Taipei City, Taipei, Taiwan
Tri-Service General Hospital ( Site 1100)
Taipei City, Taipei, Taiwan
Taoyuan General Hospital ( Site 1106)
Taoyuan, Taoyuan, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 1103)
Kaohsiung City, , Taiwan
Taichung Veterans General Hospital-Chest ( Site 1101)
Taichung, , Taiwan
National Cheng Kung University Hospital-Clinical Trial Center ( Site 1102)
Tainan, , Taiwan
National Taiwan University Hospital-Oncology ( Site 1104)
Taipei, , Taiwan
Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 3106)
Adana, , Turkey (Türkiye)
Gulhane Egitim Arastirma Hastanesi-Onkoloji ( Site 3104)
Ankara, , Turkey (Türkiye)
Hacettepe Universite Hastaneleri-oncology hospital ( Site 3101)
Ankara, , Turkey (Türkiye)
Memorial Ankara Hastanesi-Medical Oncology ( Site 3110)
Ankara, , Turkey (Türkiye)
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 3103)
Ankara, , Turkey (Türkiye)
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 3107)
Istanbul, , Turkey (Türkiye)
Addenbrooke's Hospital ( Site 3217)
Cambridge, Cambridgeshire, United Kingdom
Mount Vernon Hospital ( Site 3218)
Northwood, Hillingdon, United Kingdom
St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 3203)
London, London, City of, United Kingdom
Churchill Hospital ( Site 3219)
Oxford, Oxfordshire, United Kingdom
Freeman Hospital-Northern Centre for Cancer Care ( Site 3212)
Newcastle upon Tyne, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-508012-35-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
MK-2870-019
Identifier Type: OTHER
Identifier Source: secondary_id
jRCT2021240020
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1297-4260
Identifier Type: OTHER
Identifier Source: secondary_id
2870-019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.